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Trachoma is almost exclusively a disease of poor families and communities living in developing countries. It accounts for 15% of blindness worldwide—around 
6 million people [1]. Although the disease is avoidable, it 
continues to blind. With so few voices speaking out on behalf 
of people affected by trachoma, it remains a neglected public 
health issue.
Epidemiology
Trachoma, a chronic keratoconjunctivitis, is caused by 
episodes of infection with Chlamydia trachomatis, an obligate 
intracellular bacterium. Only serovars A, B, Ba, and C are 
implicated in trachoma. 
Trachoma is the second leading cause of blindness 
worldwide [1]. According to the World Health Organization, 
currently 84 million people, mostly children, have active 
disease, and another 7.6 million people have trichiasis—a 
stage of trachoma in which the upper eyelid turns inward 
and one or more eyelashes rub against the eyeball [2]. An 
estimated 10% of the world’s population lives in endemic 
areas and is at risk of developing trachoma. Global loss of 
productivity related to impaired vision and blindness from 
trachoma is thought to be as high as $US 5.3 billion annually 
[3]. More than 55 countries have been identiﬁ ed as endemic 
for trachoma, most of them in Africa and Asia (Figure 1) [4].
Humankind has known trachoma since antiquity. Ibn-e-
Isa, an Arab physician, was the ﬁ rst person to describe the 
different stages of trachoma and noted trichiasis as one of its 
sequelae. So prevalent was the disease not so long ago that 
trachoma hospitals were established in many parts of Europe 
and America [5]. The disease then declined dramatically in 
what is now called the developed world, mainly because of 
socioeconomic development [4]. 
Transmission occurs from eye to eye via hands, clothing, 
and other fomites. Flies have been identiﬁ ed as a major vector 
for the infection’s spread [6]. The presence of open latrines 
favors the vector population (Figure 2). Factors associated 
with trachoma include the extent to which the water supply 
is limited, the distance from the water source, the amount 
of water used for washing purposes, and overcrowding [7]. 
One case-control study in a Gambian village compared water 
use in 18 families having one or more active trachoma cases 
among the children with that in 16 trachoma-free families 
in the same village. The families with trachoma were found 
to use signiﬁ cantly less water per person per day for washing 
children than did the control group [8]. 
The Neglected Diseases section focuses attention either on a specifi c disease or 
describes a novel strategy for approaching neglected health issues in general.
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Figure 1. The Worldwide Distribution of Trachoma 
(Map: Silvio Mariotti/WHO) 
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The disease tends to cluster in certain communities within 
a village and certain families within a neighborhood. Women, 
especially in rural areas, are affected twice as often as men 
[9]. 
Clinical Manifestations and Grading 
Trachoma initially presents in childhood as red eye—itching, 
redness, and pain. The essential lesion is a trachomatous 
follicle (lymphoid cell aggregate) occurring typically in 
the upper tarsal conjunctiva (Figure 3). The roughened 
appearance of the upper tarsal conjunctiva gives the 
disease its name (trachoma is the Greek word for “rough”). 
Trachomatous involvement of the cornea manifests itself 
initially as superﬁ cial keratitis. At a later stage, pannus 
formation (new vessel growth) may occur over the margin of 
the cornea, usually limited to the upper half.
In a subgroup of individuals, ﬁ brosis occurs because of 
repeated infections, resulting in scarring of the conjunctiva 
(scarring trachoma). In scarring trachoma, the upper eyelid 
is shortened and distorted (entropion) and the lashes 
abrade the eye (trichiasis). Blindness results from corneal 
opaciﬁ cation, which is related to the degree of entropion or 
trichiasis [10]. 
Based on the presence or absence of some of the key signs 
of the disease, WHO has developed a simpliﬁ ed grading 
system for the assessment of trachoma (Figure 3) [11,12]. 
The system can easily be used by non-specialists, after 
appropriate training, for the assessment of disease at the 
community level.
Herbert’s pits (healed follicles in the superior limbus) and 
Arlt’s line (a horizontal scar on the upper tarsal conjunctiva) 
are two other classical features of the disease.
Managing Trachoma: The SAFE Strategy 
WHO currently recommends the “SAFE” strategy for 
the management of trachoma: Surgery for trichiasis, 
Antibiotics for active disease, Facial hygiene, Environmental 
improvement to reduce the transmission of the disease 
[13,14,15].
Surgery. People with trachomatous trichiasis are at risk of 
blindness, and so treating these people is the ﬁ rst priority 
for the SAFE strategy. An evidence-based review of the SAFE 
strategy found that trichiasis surgery can alleviate discomfort 
and improve vision, though the evidence is less clear on 
whether such surgery prevents corneal opaciﬁ cation [14]. 
The review authors suggested that a protective effect of 
surgery against opaciﬁ cation is likely.
There are different types of surgical procedures to correct 
trachomatous trichiasis [16]. Their high costs and the lack of 
surgical expertise in endemic regions, however, restrict the 
use of many of these as public health interventions. On the 
basis of a controlled trial by Reacher and colleagues [16], 
WHO recommends the bilamellar tarsal rotation procedure 
as the preferred technique; it is easy to perform and easy 
to learn [17]. Surgical effectiveness is deﬁ ned in terms of 
recurrence of trichiasis; in the controlled trial, bilamellar 
tarsal rotation produced a recurrence rate of around 20% at 
follow-up 9–21 months after surgery, while other procedures 
saw 60% of patients with recurrence of trichiasis in the same 
period [16]. In several countries, different levels of health 
staff, including nurses and ophthalmic assistants, have been 
trained to perform the bilamellar tarsal rotation procedure.  
In addition to recurrence, there are other problems with 
the surgical approach to managing trachoma. It cannot 
correct all the complications, such as dry eyes. Even more 
important, and the main obstacle to preventing blindness 
from trachoma, is the low rate of uptake of surgery by 
communities with trachomatous trichiasis [14]. Barriers to 
uptake include distance to travel to surgery, perceived cost of 
the operation, child care duties, and lack of awareness about 
the treatment [14]. In Tanzania, less than a ﬁ fth of women 
with trichiasis opted for surgery, even when it was offered for 
free [18]. 
Offering surgery at the community level, rather than in 
distant medical facilities, is one strategy that could reduce 
travel times and costs and increase uptake. A cluster 
randomized controlled trial of village-based surgery versus 
health-center-based surgery in Gambia found a signiﬁ cantly 
higher uptake rate with the village-based service [19]. 
Antibiotics. The use of antibiotics aims to treat active 
infection and eliminate the reservoir. WHO currently 
recommends two regimens for the treatment of trachoma 
in endemic regions. These are 1% topical tetracycline 
ointment (twice daily for six weeks) or a single dose of oral 
azithromycin (1 g in adults and 20 mg/kg in children) [20].  
Although antibiotics are a cornerstone of the SAFE 
strategy, clinical trials of antibiotics versus control (no 
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Figure 2. A Typical Community in Which Trachoma Is Endemic 
Some of the factors linked with the continued presence of the 
disease in affected communities are lack of access to water, 
overcrowding, lack of facial hygiene, eye-seeking bazaar ﬂ ies, and 
open latrines. (Illustration: Aslam Bashir, Aga Khan University)
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treatment, placebo, or vitamin tablets) have produced 
conﬂ icting results and are difﬁ cult to pool because of 
their heterogeneity. A recent Cochrane systematic review 
concluded “there is some evidence that antibiotics reduce 
active trachoma but results are not consistent and cannot be 
pooled” [20]. The review also found that “oral treatment is 
neither more nor less effective than topical treatment” [20].
Several questions remain about the use of antibiotics, 
such as who should receive them and how often. Lietman 
and colleagues have developed a mathematical model of 
frequency of treatment that uses available epidemiological 
data from a variety of countries [21]. Based on their model, 
they recommend that in areas where trachoma is moderately 
prevalent (less than 35% of children with active infection), 
it should be treated annually, but in hyperendemic areas 
(more than 50% of children with active infection), it should 
be treated biannually. Such models, however, need to be 
validated by well-designed clinical trials.
Facial hygiene. Good facial hygiene aims to reduce 
transmission, the risk of autoinfection in a community, and 
the risk of attracting ﬂ ies [13,15]. Many cross-sectional surveys 
have shown that children with clean faces are less likely to 
have trachoma, and are less likely to have severe trachoma 
[14]. A recent study in Mali found dirtiness of the face to be 
the most important risk factor associated with trachoma [22]. 
A Cochrane systematic review found evidence that face 
washing combined with topical tetracycline can be effective in 
reducing severe active trachoma [23]. However, the evidence 
does not support a beneﬁ cial effect of face washing alone 
or in combination with topical tetracycline in reducing non-
severe active trachoma [23].
Interventions aimed at promoting facial hygiene have not 
yielded expected results in all settings, as behavioral change is 
not always readily achievable.
Environmental improvement. This component of the 
SAFE strategy also aims to reduce transmission of trachoma 
by eliminating or reducing its risk factors, some of which are 
ubiquitous while others are speciﬁ c to a region. Improving 
access to water is a key element. Other measures, such as 
provision of latrines to reduce the ﬂ y population, have also 
been found effective in reducing transmission [6]. Such 
environmental improvements will also provide other health 
beneﬁ ts to a community, such as reduction in the incidence 
of diarrhea.
As mentioned previously, there is an important association 
between water and trachoma—though the association is not 
a simple one. The distance to the water source constrains 
the amount of water used for hygiene practices. Improving 
access to water on its own, however, may not be enough. In 
the case-control study in Gambia, families with trachoma 
used less water per person per day for washing children 
than families without the disease, regardless of the amount 
of water available [8]. In other words, interventions aimed 
at increasing the availability of water should also promote 
its appropriate use. Getting community “buy in” for these 
interventions is important.
Why Is Trachoma So Neglected?
Trachoma is a disease of poor, underprivileged, and 
socioeconomically disadvantaged communities. It affects 
people who have little or no say in public decision 
making [24]. Investing in trachoma may sometimes mean 
compromising on other important issues. Many countries 
in which trachoma is endemic are also marred by regional 
conﬂ icts, civil wars, and widespread corruption. Scarce 
resources are being spent on arms and debt servicing. These 
countries often lack the political commitment needed to ﬁ ght 
against the disease. In addition, there is a lack of commitment 
by international donors.
Still, there is some room for optimism, given WHO’s 
vision of the global elimination of trachoma by the year 
2020 and the efforts of the International Trachoma 
Initiative and other non-governmental organizations. The 
implementation of the SAFE strategy to eliminate blinding 
trachoma has already proven effective in several countries 
[25]. Many countries have already started trying to eliminate 
trachoma themselves.
Future Directions
Although the new initiatives in trachoma control are 
encouraging, trachoma elimination programs clearly need 
to be extended to many more countries. In addition, there 
are three crucial steps that still need to be undertaken if 
blindness from trachoma is to be eliminated. 
First, there needs to be more emphasis on the “F” and “E” 
components of the SAFE strategy. Antibiotics and surgery 
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Figure 3. WHO Simplifi ed Grading System: A Guide for the Assessment of 
Trachoma 
(Photos: from [11], with permission from WHO)
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alone will not eliminate trachoma; work also needs to be done 
to eliminate the risk factors and decrease the transmission 
of the disease in affected communities. Such primary 
prevention is more likely to have a sustainable impact but 
requires a prolonged effort and investment [15,24]. Because 
elimination of trachoma requires improvement in education 
and hygiene practices, improved accessibility to water, and 
economic development of endemic regions, collaboration 
among departments and ministries is vital. An example of 
such collaboration is the recent involvement of the Water 
Supply and Sanitation Collaborative Council (www.wsscc.org) 
in trachoma control efforts. Similar partnerships need to be 
strengthened [25]. Socioeconomic development must be at the 
heart of control efforts—trachoma was eradicated from much 
of the developed world even before the advent of antibiotic 
programs for trachoma, and much of this eradication was 
attributable to socioeconomic development [26].
Second, research into different aspects of the disease 
should continue. Work on a vaccine for trachoma, although 
not successful thus far, should receive more attention [10]. 
Future research should look at risk factors for trachoma in 
diverse communities and at barriers to implementation of the 
SAFE strategy.
Third, awareness about the disease and the SAFE strategy 
need to be promoted globally. At the same time, local, cost-
effective solutions to trachoma need to be encouraged. 
Provision of pit latrines to reduce ﬂ y populations is just one 
such measure [6]. 
Unless these steps are taken, trachoma will continue to be 
a major cause of blindness in communities in the developing 
world [24]. 
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